JP2007520537A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007520537A5 JP2007520537A5 JP2006551904A JP2006551904A JP2007520537A5 JP 2007520537 A5 JP2007520537 A5 JP 2007520537A5 JP 2006551904 A JP2006551904 A JP 2006551904A JP 2006551904 A JP2006551904 A JP 2006551904A JP 2007520537 A5 JP2007520537 A5 JP 2007520537A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- chlorophenylamino
- amide
- carboxylic acid
- acceptable derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- HZXOTOOHIVUIJU-UHFFFAOYSA-N 2-(3-chloroanilino)-4-[1-(dimethylamino)ethyl]-n-(oxan-4-ylmethyl)pyrimidine-5-carboxamide;hydrochloride Chemical compound Cl.N=1C=C(C(=O)NCC2CCOCC2)C(C(N(C)C)C)=NC=1NC1=CC=CC(Cl)=C1 HZXOTOOHIVUIJU-UHFFFAOYSA-N 0.000 claims 1
- WVYZUZIUQXMOHF-UHFFFAOYSA-N 2-(3-chloroanilino)-4-ethyl-n-(oxan-4-ylmethyl)pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NCC2CCOCC2)C(CC)=NC=1NC1=CC=CC(Cl)=C1 WVYZUZIUQXMOHF-UHFFFAOYSA-N 0.000 claims 1
- ZJERRCJPKOZJGT-UHFFFAOYSA-N 2-(3-chloroanilino)-n-(oxan-4-ylmethyl)-4-propan-2-ylpyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NCC2CCOCC2)C(C(C)C)=NC=1NC1=CC=CC(Cl)=C1 ZJERRCJPKOZJGT-UHFFFAOYSA-N 0.000 claims 1
- ZKWKIJXNDPVRFZ-UHFFFAOYSA-N 2-(3-chloroanilino)-n-cyclohexyl-4-ethyl-n-methylpyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)N(C)C2CCCCC2)C(CC)=NC=1NC1=CC=CC(Cl)=C1 ZKWKIJXNDPVRFZ-UHFFFAOYSA-N 0.000 claims 1
- PZRWJUYHONADFH-UHFFFAOYSA-N 2-(3-chloroanilino)-n-cyclohexyl-n-methyl-4-propan-2-ylpyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)N(C)C2CCCCC2)C(C(C)C)=NC=1NC1=CC=CC(Cl)=C1 PZRWJUYHONADFH-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 3
- 206010041250 Social phobia Diseases 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000022214 Post-traumatic amnestic disease Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 208000025319 neurotic depression Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000018726 traumatic encephalopathy Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0402356.0A GB0402356D0 (en) | 2004-02-03 | 2004-02-03 | Novel compounds |
| PCT/GB2005/000341 WO2005075440A1 (en) | 2004-02-03 | 2005-02-01 | 2- (phenylamino) -pyrimidin-5-amides as cannabinoid 2 receptors modulators for the treatment of immune or inflammatory disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007520537A JP2007520537A (ja) | 2007-07-26 |
| JP2007520537A5 true JP2007520537A5 (https=) | 2008-03-21 |
Family
ID=31985568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551904A Withdrawn JP2007520537A (ja) | 2004-02-03 | 2005-02-01 | 免疫病または炎症障害を治療するためのカンナビノイド２受容体の調節剤としての２−（フェニルアミノ）−ピリミジン−５−アミド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090264452A1 (https=) |
| EP (1) | EP1711475A1 (https=) |
| JP (1) | JP2007520537A (https=) |
| GB (1) | GB0402356D0 (https=) |
| WO (1) | WO2005075440A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007125049A1 (en) * | 2006-04-27 | 2007-11-08 | Solvay Pharmaceuticals Gmbh | Use of cbx cannabinoid receptor modulators as potassium channel modulators |
| US7763607B2 (en) | 2006-04-27 | 2010-07-27 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| KR20120002581A (ko) | 2009-03-30 | 2012-01-06 | 아스텔라스세이야쿠 가부시키가이샤 | 피리미딘 화합물 |
| CN113109571B (zh) * | 2021-03-19 | 2023-05-05 | 浙江工商大学 | 一种用于评估个体过敏程度的试剂盒 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112820A (en) * | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| HUT63941A (en) * | 1992-05-15 | 1993-11-29 | Hoechst Ag | Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same |
| CA2230894A1 (en) * | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
| FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| US20020183335A1 (en) * | 2001-02-20 | 2002-12-05 | Piyasena Hewawasam | 2, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators |
| UY27939A1 (es) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| US20060247261A1 (en) * | 2002-08-21 | 2006-11-02 | Eatherton Andrew J | Pyrimidine compounds |
| GB0222493D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
| GB0222495D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
-
2004
- 2004-02-03 GB GBGB0402356.0A patent/GB0402356D0/en not_active Ceased
-
2005
- 2005-02-01 WO PCT/GB2005/000341 patent/WO2005075440A1/en not_active Ceased
- 2005-02-01 US US10/597,476 patent/US20090264452A1/en not_active Abandoned
- 2005-02-01 JP JP2006551904A patent/JP2007520537A/ja not_active Withdrawn
- 2005-02-01 EP EP05702083A patent/EP1711475A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2293731C2 (ru) | Производные пиридина и пиримидина, способы их получения (варианты), фармацевтическая композиция и применение | |
| CN101679287B (zh) | 烟碱型乙酰胆碱受体调节剂 | |
| KR101562835B1 (ko) | 치료제 | |
| CN1419552A (zh) | 2－氨基－3－烷基嘧啶酮衍生物作为GSK3β抑制剂 | |
| JP2007520539A5 (https=) | ||
| TWI224102B (en) | Serotonergic agents | |
| AU2016370554A1 (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| JP2013537887A5 (https=) | ||
| JP2005526723A5 (https=) | ||
| JP2009539762A (ja) | Ｈ３受容体のテトラリン拮抗薬 | |
| JP2010506851A (ja) | 二環式ヘテロ芳香族化合物 | |
| MXPA04007502A (es) | Derivados de quinolina como antagonistas de neuropeptido y (npy). | |
| JP2008501758A5 (https=) | ||
| ES2222396T3 (es) | Compuestos utiles como ingrediente activo de un medicamento para el tratamiento preventivo y/o terapeutico de enfermedades neurodegenerativas. | |
| CN107108478A (zh) | Urat1抑制剂 | |
| JP6929857B2 (ja) | ６，７，８，９−テトラヒドロ−５Ｈ−ピリド［２，３−ｄ］アゼピンドーパミンＤ３リガンド | |
| JP5822079B2 (ja) | 疼痛治療剤 | |
| JP2008543782A (ja) | ５−ｈｔ１ａ受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト | |
| JP2014518281A (ja) | 電位依存性ナトリウムチャネル遮断薬 | |
| JP2009542661A5 (https=) | ||
| JP4885709B2 (ja) | ピリジニルアセトニトリル類 | |
| JP2007523206A5 (https=) | ||
| JP2007520537A5 (https=) | ||
| JPWO2008029924A1 (ja) | 環状アミノアルキルカルボキサミド誘導体 | |
| JP2006117568A (ja) | チオフェン環を有する新規アミド誘導体及びその医薬としての用途 |